Phase II evaluation of maytansine in patients with metastatic lung cancer. - Suppr | 超能文献

Phase II evaluation of maytansine in patients with metastatic lung cancer.

作者信息

Eagan R T, Creagan E T, Ingle J N, Frytak S, Rubin J

出版信息

Cancer Treat Rep. 1978 Oct;62(10):1577-9.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Phase II evaluation of maytansine in patients with metastatic lung cancer.

Cancer Treat Rep. 1978 Oct;62(10):1577-9.

2

Phase II trial of maytansine in patients with advanced colorectal carcinoma.美登素用于晚期结直肠癌患者的II期试验。

Cancer Treat Rep. 1978 Aug;62(8):1237-8.

3

Phase II study of maytansine in advanced sarcomas.

Cancer Treat Rep. 1983 Apr;67(4):401-2.

4

Phase II evaluation of maytansine in patients with advanced head and neck cancer.

Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2061-2.

5

Phase II study of maytansine in advanced breast cancer.

Cancer Treat Rep. 1981 May-Jun;65(5-6):536-7.

6

Maytansine: a phase I study of an ansa macrolide with antitumor activity.

Cancer Treat Rep. 1978 Mar;62(3):435-8.

7

Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study.

Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1115-7.

8

Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group.美登素、低剂量氯脲霉素和高剂量氯脲霉素作为单一药物治疗晚期可测量胰腺腺癌的II期试验。胃肠道肿瘤研究组。

Cancer Treat Rep. 1985 Apr;69(4):417-20.

9

Results of a phase II study of maytansine in patients with breast carcinoma and melanoma.

Cancer Treat Rep. 1979 Mar;63(3):507-9.

10

Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578).顺铂、美登素和氯脲霉素治疗小细胞肺癌的II期研究（EST 2578）

Cancer Treat Rep. 1982 Jun;66(6):1417-9.

引用本文的文献

1

Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models.依达曲妥珠单抗瑞妥昔单抗对三阴性乳腺癌的临床前肿瘤模型的作用。

Pharm Res. 2018 Apr 17;35(6):118. doi: 10.1007/s11095-018-2400-y.

2

Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.儿科临床前试验计划对抗体-美登素偶联物 IMGN901（Lorvotuzumab mertansine）进行初步测试（第 1 阶段）。

Pediatr Blood Cancer. 2013 Nov;60(11):1860-7. doi: 10.1002/pbc.24647. Epub 2013 Jun 24.

3

Antibody-DM1 conjugates as cancer therapeutics.抗体药物偶联物作为癌症治疗药物。

Cancer Lett. 2011 Aug 28;307(2):113-8. doi: 10.1016/j.canlet.2011.03.017. Epub 2011 Apr 9.

4

Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review.晚期肺腺癌的单药化疗。综述。

Cancer Chemother Pharmacol. 1988;21(2):89-102. doi: 10.1007/BF00257354.